| Name | Tegaserod |
| Description | Tegaserod is an orally available 5-HT4R agonist and 5-HT2B receptor antagonist with inhibitory effects on various 5-hydroxytryptamine receptors. Tegaserod has antitumor activity and is used in the treatment of irritable bowel syndrome (IBS). |
| In vitro | Tegaserod ( 3,5 μM; 24,48,72 h ) increased the apoptosis of A375, RPMI-7951 ( RPMI ), SH4, B16F10, MeWo and MEL-JUSO cell lines in a time- and dose-dependent manner[1]. |
| In vivo | After subcutaneous injection of B16F10 cells in C57BL / 6J mice, tegaserod ( 5 mg / kg ; 1 times a day for 5 consecutive days ) significantly reduced tumor growth, and only a slight decrease in body weight was observed after treatment[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (16.59 mM), Sonication is recommended. DMSO : 257.5 mg/mL (854.37 mM), Sonication is recommended.
|
| Keywords | 5HTReceptor | 5-HT4 | 5-HT2B | 5HT Receptor |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |